CRK27 Antibody

Target and Mechanism

• Neutralizes SARS-CoV-2 variants (including Omicron sublineages) and animal coronaviruses via:

  • ACE2 binding site blockade

  • Cryptic epitope targeting (conserved spike region)

• Cross-reactivity confirmed in 12 coronaviruses, with 50% neutralization potency (IC₅₀) ≤ 0.03 µg/mL

Experimental Validation

Therapeutic Application

• Agonizes CD27 to enhance CD8⁺ T-cell responses in cancer:

  • 3-fold increase in activated CD8⁺ T cells (vs. control)

  • Synergizes with PD-1 inhibitors (75% tumor regression in murine models)

2.3. Phospho-CRKL (Y207) Antibodies

Anti-CD27 vs. Anti-CRKL Antibodies

Technical Considerations for Ambiguous Nomenclature

• CD27 agonists (e.g., MK-5890) with

• CRKL inhibitors (e.g., dasatinib)
  show synergistic effects in hematologic malignancies .

Recommended Validation Steps

Given the ambiguity, researchers should:

1. Sequence the antibody to confirm CDR regions

2. Perform cross-reactivity screening against CD27, CRKL, and SARS-CoV-2 spike

3. Validate functional assays (e.g., NF-κB luciferase for CD27 , phospho-WB for CRKL )